Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matuzumab + ECX in Metastatic Esophago-Gastric Adenocarcinoma
NCT00215644Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2005
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of matuzumab in esophageal cancer and gastric cancer (GC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Objective Response Rate up to 3 years. Started Aug 2005; status: completed.
02
Drugs
matuzumab
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT00215644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215644.